High Flow Nasal Cannula Therapy in Bronchiolitis : Early vs Rescue
-
- STATUS
- Recruiting
-
- End date
- Jun 1, 2023
-
- participants needed
- 350
-
- sponsor
- Hamad Medical Corporation
Summary
The enrolled RSV-bronchiolitis patients will be randomized into two arms , the early HHHFNC group and the standard therapy group with rescue HHHFNC to study the efficacy of this treatment.
Description
- Setting
The study will be conducted between June 2017 and June 2020 in the short stay unit of the Pediatric Emergency Center (PEC) of Hamad General Hospital, the only pediatric emergency facility in the State of Qatar. Infants aged 3 months presenting to the unit for treatment of viral bronchiolitis with positive RSV test will be eligible for the study.
- Procedure
Eligible patients will be enrolled after obtaining written consent. For patients who consent, plain chest radiography, and nasopharyngeal swabs will be taken for RSV detection. If the patient has a positive RSV rapid antigen test, patients will be randomized in one of the study arms. Adverse effects in each group will be carefully monitored and documented.
Study Intervention:
Patients will be randomized into two treatment arms
Group 1: Early HHHFNC Group Patients in this group will be treated by using heated humidified high flow oxygen /air via nasal cannula; investigators will keep the patient on HHHFNC until he/she becomes clinically ready for discharge.
Group 2: Standard Therapy and Rescue HHHFNC Group:
patients in this group will be treated by usual therapy,investigators will use low flow nasal cannula oxygen therapy only if oxygenation needed to maintain Oxygen saturation (SpO2) 92% , if the patient deteriorate and require ICU, rescue HHHFNC will be started before admission to the ICU.
Details
| Condition | Bronchiolitis, Respiratory Syncytial Virus (RSV) |
|---|---|
| Treatment | Heated Humidified High Flow Nasal Cannula, Standard Therapy (Low Flow Nasal Cannula) |
| Clinical Study Identifier | NCT03095495 |
| Sponsor | Hamad Medical Corporation |
| Last Modified on | 27 February 2022 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer